THERAPY DOSSIER · th-441aeb88c621

Pifithrin-mu (PFT-mu, 2-phenylethynesulfonamide)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29962076 ↗2018Reported benefit

Pifithrin-mu modulates microglial activation and promotes histological recovery following spinal cord injury.

MouseSpinal cord injuryContusionC57BL/6FemaleAdministered during the acute phase of injury

Model: Spinal cord contusion injury

Pifithrin-mu attenuated microglial activation in vitro and, given during the acute phase, reduced lesion size and the number of pro-inflammatory microglia and macrophages, maintaining a more anti-inflammatory environment after a single dose.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…